Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
230 hedge funds and large institutions have $1.59B invested in Sage Therapeutics in 2020 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 84 increasing their positions, 64 reducing their positions, and 84 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 64
7% more call options, than puts
Call options by funds: $14.8M | Put options by funds: $13.8M
1.76% less ownership
Funds ownership: 108.08% → 106.31% (-1.8%)
14% less funds holding
Funds holding: 267 → 230 (-37)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
40% less first-time investments, than exits
New positions opened: 50 | Existing positions closed: 84
61% less capital invested
Capital invested by funds: $4.04B → $1.59B (-$2.45B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$68.5M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$59.6M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$57.9M |
| 4 |
Morgan Stanley
New York
|
+$52.6M |
| 5 |
Renaissance Technologies
New York
|
+$36.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$155M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$70.4M |
| 3 |
Janus Henderson Group
London,
|
-$59.4M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
-$39.7M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$37.9M |
SAGE Hedge Fund Activity: Q1 2020 in Review
230 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q1 2020, worth a combined $1.59B — down 61% from $4.04B a quarter earlier.
Sellers outnumbered buyers: 84 funds closed out of SAGE and 50 opened new positions — a net loss of 34 holders — while 64 trimmed existing stakes and 84 added.
The largest buyer was Boxer Capital, adding an estimated $68.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $155M.
- 230 institutional investors held Sage Therapeutics (SAGE) as of Q1 2020, down from 267 in Q4 2019.
- Funds reported $1.59B of Sage Therapeutics stock for Q1 2020, down 61% quarter-over-quarter.
- 50 funds opened new Sage Therapeutics positions in Q1 2020 and 84 closed out, a net change of -34 holders.
- The largest Sage Therapeutics buyer in Q1 2020 was Boxer Capital, an estimated $68.5M added.
- The largest Sage Therapeutics seller in Q1 2020 was T. Rowe Price Associates, an estimated $155M sold.
Based on aggregated 13F filings for Q1 2020.